Intuitive Surgical, Inc. (ISRG) Stock Analysis
Is ISRG a good investment?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 76.0/100 as of August 21, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Fortress balance sheet with zero debt (D/E: N/A vs. industry 0.568), $5.22B cash, and $2.62B annual FCF — financial distress risk is essentially zero; the company self-funds all growth, R&D, and potential acquisitions without capital markets dependency, providing a durable compounding engine regardless of macro conditions. Main concern: Near-term EPS growth deceleration remains unresolved: next-year EPS growth of 11.9% is 54.6% below the industry average of 26.2%, and Headline #1 ('Intuitive Surgical Stock Is Having Its Worst Year Since 2008') and the noted 'US procedure growth slowed in Q2 2026' confirm that softer U.S. surgical volumes are a real near-term headwind — any further guidance cut could pressure the already-modest 11.9% EPS growth estimate and trigger multiple compression from the current 42.9x P/E.
Investment Summary
Intuitive Surgical (ISRG) is an exceptional business trading at a meaningfully improved valuation after a 6.7% pullback from $401.27 to $374.48 over the past week. The stock now sits near the lower bound of our prior recommended entry zone ($375-$395), making this a more attractive entry point than 7 days ago. Core fundamentals remain world-class: 66.7% gross margin, 33.6% operating margin, 28.4% net margin, zero debt (D/E: N/A vs. industry 0.568), $5.22B cash, and $2.62B annual FCF. The PEG ratio has improved from 2.21 to 2.06 — returning to the level that justified our prior Buy recommendation — driven entirely by the price decline rather than any fundamental deterioration. The P/E has compressed from 46x to 42.9x, improving the growth-adjusted valuation. The analyst consensus target of $479.86 implies 28.1% upside from current levels. News sentiment is constructive at 84.9/100 (11 positive, 1 negative, 2 neutral), with Asia Pacific manufacturing expansion, analyst 'buy on the dip' calls, and a strengthening digital ecosystem. The primary concern — near-term EPS growth of 11.9% vs. industry 26.2% — remains unresolved, but the price decline has partially compensated for this. The stock is now at the entry zone we specified last week, making this the actionable moment.
Key Strengths
- Fortress balance sheet with zero debt (D/E: N/A vs. industry 0.568), $5.22B cash, and $2.62B annual FCF — financial distress risk is essentially zero; the company self-funds all growth, R&D, and potential acquisitions without capital markets dependency, providing a durable compounding engine regardless of macro conditions
- Unmatched sector profitability: 66.7% gross margin (53.5% above industry 43.4%), 33.6% operating margin (vs. industry -278.7%), 28.4% net margin (vs. industry -334.5%) — da Vinci platform's high switching costs, surgeon training ecosystem, and razor-and-blade recurring instrument/service revenue create a durable earnings engine that peers cannot replicate; P/E of 42.9x is 33.1% BELOW the industry average of 64.2x despite superior quality
- Constructive news environment (84.9/100, 11 positive) with Asia Pacific manufacturing expansion (Headline #3: 'Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific' — positive because it signals capacity investment to support international growth, a key driver of the 15.1% 5-year EPS CAGR), analyst 'buy on the dip' calls, and stock now trading 28.1% below the $479.86 analyst consensus target — the 6.7% pullback has created the entry opportunity our prior report anticipated
Key Concerns
- Near-term EPS growth deceleration remains unresolved: next-year EPS growth of 11.9% is 54.6% below the industry average of 26.2%, and Headline #1 ('Intuitive Surgical Stock Is Having Its Worst Year Since 2008') and the noted 'US procedure growth slowed in Q2 2026' confirm that softer U.S. surgical volumes are a real near-term headwind — any further guidance cut could pressure the already-modest 11.9% EPS growth estimate and trigger multiple compression from the current 42.9x P/E
- PEG ratio of 2.06 (using 5-year growth) and approximately 3.6x (using next-year growth of 11.9%) still signals the stock is priced for near-perfection with limited margin of safety — while the 6.7% pullback improved the entry, the stock remains above the $340-$375 range where a disciplined value investor would have high conviction; any macro shock, earnings miss, or ACA-related elective surgery volume decline could accelerate the downside toward the $330-$350 support zone
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ISRG's fundamentals are unchanged from the prior report — the 6.7% price decline is purely valuation-driven, not fundamental deterioration. Profitability: Gross margin 66.7% (vs. industry 43.4%, +53.5% premium), operating margin 33.6% (vs. industry -278.7%, categorically superior), net margin 28.4% (vs. industry -334.5%), ROE 17.4% (vs. industry -0.4%) — all generated with zero financial leverage. Financial Health: D/E of N/A (effectively zero) vs. industry 0.568, $5.22B cash, $2.62B FCF — fortress balance sheet. Growth: Revenue growth 18.5% YoY (2.1x industry rate of 8.7%), historical EPS growth 26.5% (vs. industry 17.2%), but forward next-year EPS growth of only 11.9% (vs. industry 26.2%, -54.6% gap) remains the central concern. 5-year EPS CAGR of 15.1% is 32.7% above the industry average of 11.4%. Valuation: P/E of 42.9x (33.1% BELOW industry average of 64.2x — a genuine relative discount), PEG of 2.06 using 5-year growth (essentially in line with industry PEG of 2.01), but PEG of ~3.6x using next-year growth of 11.9% signals near-term overvaluation. P/B of 7.29x reflects intangible asset value. DCF intrinsic value range of $350-$420 places current price of $374.48 near the lower bound of fair value — a meaningful improvement from $401.27 which was above the midpoint.
News Sentiment
Intuitive Surgical is navigating one of its most challenging years in nearly two decades, but Wall Street analysts are increasingly calling it a buying opportunity. The maker of the iconic da Vinci surgical robot has seen its stock slide significantly in 2026 — Headline #1 notes it's 'Having Its Worst Year Since 2008' — driven by a slowdown in U.S. surgical procedure volumes in Q2 2026 that spooked investors accustomed to the company's relentless growth. But here's the thing: the underlying business remains remarkably strong. The company is doubling down on its global ambitions, with Headline #3 revealing it's expanding its manufacturing footprint in Asia Pacific — a strategic move to capture the massive untapped surgical robotics market across the region. Meanwhile, Headline #2 asks whether ISRG's software strategy is becoming as important as its robots — and the answer appears to be yes, with a strengthening digital ecosystem creating deeper customer lock-in that makes hospitals even less likely to switch away from da Vinci systems. At least one prominent Wall Street analyst is recommending investors 'buy on the dip,' noting the stock now trades roughly 28% below the average analyst price target of $479.86. Headline #5 captures the tension perfectly: the stock 'slides further but one Wall Street analyst' sees opportunity. For long-term investors, the story is about a dominant franchise temporarily pressured by near-term volume headwinds — not a broken business model.
Risk Assessment
PRIMARY RISK: Near-term EPS growth of 11.9% vs. industry 26.2% — if Q3 2026 earnings disappoint or guidance is cut, the P/E of 42.9x could compress toward 35-38x, implying a stock price of $305-$330 (15-20% downside from entry). SECONDARY RISK: U.S. procedure volume slowdown (Q2 2026 noted as a headwind) — ACA enhanced premium expiration could reduce elective surgical volumes, directly pressuring ISRG's instrument/service recurring revenue. TERTIARY RISK: Headline #1 ('Worst Year Since 2008') signals negative technical momentum and potential institutional selling pressure. MITIGATION: (1) Entry at $365-$385 rather than current price provides a 2.7-5.4% buffer; (2) Stop-loss at $340 limits downside to approximately 9.3% from entry midpoint of $375; (3) Position size of 3.5% (not 5%+) reflects Medium conviction; (4) The $5.22B cash balance and zero debt mean ISRG can weather a prolonged volume slowdown without existential risk. UPSIDE SCENARIO: Da Vinci 5 upgrade cycle accelerates, Ion platform ramp exceeds expectations, Asia Pacific expansion drives international revenue above 18.5% growth — could push toward $480-$530 target range within 12-18 months.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ISRG a halal stock?
No, Intuitive Surgical, Inc. (ISRG) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ISRG?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 76.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ISRG a good investment?
According to Plutrex AI, ISRG has a Buy rating (76.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ISRG?
US stocks like ISRG can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ISRG?
Plutrex AI identifies the main risks for ISRG by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.